Insmed's experimental drug, brensocatib, reduces lung disease symptoms and may be the first treatment for non-cystic fibrosis bronchiectasis.

Insmed shares surge 131% after experimental drug reduces lung disease symptoms. Insmed's brensocatib demonstrated statistically significant reductions in pulmonary exacerbations in a Phase 3 study for non-cystic fibrosis bronchiectasis. If approved, it would be the first treatment for the disease. The company plans to file for US market clearance in Q4 2024 and launch the drug in mid-2025.